2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1325-1336. PMID: 35918106, PMCID: PMC9625096, DOI: 10.2215/cjn.00550122.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsTimes weekly dosingTRIAL REGISTRY NAMESecondary end pointsTreatment of anemiaEpoetin groupDaprodustat groupEnd pointWeekly dosingREGISTRY NAMEHemoglobin valuesMean changeHypoxia-inducible factor prolyl hydroxylase inhibitorCLINICAL TRIAL REGISTRY NAMEPrincipal secondary end pointTreatment-emergent adverse eventsIntravenous iron doseIntravenous iron usePrimary end pointChronic kidney diseaseMean hemoglobin valuesEvaluation periodProlyl hydroxylase inhibitorBaseline hemoglobinPrevalent hemodialysis
2020
Hypertension and kidney disease progression.
Rigo D, Orias M. Hypertension and kidney disease progression. Clinical Nephrology 2020, 93: 103-107. PMID: 31549630, DOI: 10.5414/cnp92s118.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney disease progressionDisease progressionCases of CKDHypertension-attributed nephropathyRisk of progressionAfrican American patientsGene risk variantsClinical suspicionHypertensive nephropathyKidney diseaseUnknown etiologyCommon findingProgressionHypertensionNephropathyPatientsRisk variantsGenetic backgroundEtiologyDiseaseDiagnosisSuspicion
2013
Does Kidney Disease Cause Hypertension?
Peixoto AJ, Orias M, Desir GV. Does Kidney Disease Cause Hypertension? Current Hypertension Reports 2013, 15: 89-94. PMID: 23344662, DOI: 10.1007/s11906-013-0327-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseRenal functionStructural kidney diseaseGlomerular filtration ratePlasmin-mediated activationExtracellular fluid volumeProteinuric glomerular diseasesPolycystic kidney diseaseChronic hypertensionHypertension increasesEpithelial sodium channelSodium retentionFiltration rateGlomerular diseaseHypertensionCurrent evidenceDiseaseSodium channelsFluid volumeDetectable changeSevere reductionMost casesProteinuriaPatients
2009
Is there a role for direct renin inhibitors in chronic kidney disease?
Peixoto AJ, Orias M. Is there a role for direct renin inhibitors in chronic kidney disease? Current Opinion In Nephrology & Hypertension 2009, 18: 397-403. PMID: 19584722, DOI: 10.1097/mnh.0b013e32832e3183.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseBlood pressure controlKidney disease progressionRenin inhibitorsCardiovascular eventsKidney diseaseDisease progressionEffective blood pressure controlPressure controlHard renal endpointsEarly diabetic nephropathyNormal renal functionDirect renin inhibitorRandomized clinical trialsRenal endpointsStudy drugCardiovascular riskDiabetic nephropathyRenal functionRenal injuryImproved survivalClinical trialsAnimal modelsHuman studiesPatients